Literature DB >> 28994401

Crystal structure of type II NADH:quinone oxidoreductase from Caldalkalibacillus thermarum with an improved resolution of 2.15 Å.

Yoshio Nakatani1, Wanting Jiao2, David Aragão3, Yosuke Shimaki1, Jessica Petri1, Emily J Parker2, Gregory M Cook1.   

Abstract

Type II NADH:quinone oxidoreductase (NDH-2) is a respiratory enzyme found in the electron-transport chain of many species, with the exception of mammals. It is a 40-70 kDa single-subunit monotopic membrane protein that catalyses the oxidation of NADH and the reduction of quinone molecules via the cofactor FAD. NDH-2 is a promising new target for drug development given its essential role in many bacterial species and intracellular parasites. Only two bacterial NDH-2 structures have been reported and these structures are at moderate resolution (2.3-2.5 Å). In this communication, a new crystallization platform is reported that produced high-quality NDH-2 crystals that diffracted to high resolution (2.15 Å). The high-resolution NDH-2 structure was used for in silico quinone substrate-docking studies to investigate the binding poses of menadione and ubiquinone molecules. These studies revealed that a very limited number of molecular interactions occur at the quinone-binding site of NDH-2. Given that the conformation of the active site is well defined, this high-resolution structure is potentially suitable for in silico inhibitor-compound screening and ligand-docking applications.

Entities:  

Keywords:  NDH-2; membrane proteins; quinone binding; respiratory enzymes; type II NADH:quinone oxidoreductase

Mesh:

Substances:

Year:  2017        PMID: 28994401      PMCID: PMC5633920          DOI: 10.1107/S2053230X17013073

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  32 in total

1.  A method to produce microseed stock for use in the crystallization of biological macromolecules.

Authors:  J R Luft; G T DeTitta
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-05

2.  Novel procedure for modeling ligand/receptor induced fit effects.

Authors:  Woody Sherman; Tyler Day; Matthew P Jacobson; Richard A Friesner; Ramy Farid
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

Review 3.  The three families of respiratory NADH dehydrogenases.

Authors:  Stefan Kerscher; Stefan Dröse; Volker Zickermann; Ulrich Brandt
Journal:  Results Probl Cell Differ       Date:  2008

4.  Use of an induced fit receptor structure in virtual screening.

Authors:  Woody Sherman; Hege S Beard; Ramy Farid
Journal:  Chem Biol Drug Des       Date:  2006-01       Impact factor: 2.817

5.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.

Authors:  Ramy Farid; Tyler Day; Richard A Friesner; Robert A Pearlstein
Journal:  Bioorg Med Chem       Date:  2006-01-18       Impact factor: 3.641

Review 6.  New insights into type II NAD(P)H:quinone oxidoreductases.

Authors:  Ana M P Melo; Tiago M Bandeiras; Miguel Teixeira
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

7.  Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria.

Authors:  Giancarlo A Biagini; Parnpen Viriyavejakul; Paul M O'neill; Patrick G Bray; Stephen A Ward
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

8.  Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases.

Authors:  Ahmad Saleh; Johannes Friesen; Stefan Baumeister; Uwe Gross; Wolfgang Bohne
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

9.  Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs.

Authors:  Edward A Weinstein; Takahiro Yano; Lin-Sheng Li; David Avarbock; Andrew Avarbock; Douglas Helm; Andrew A McColm; Ken Duncan; John T Lonsdale; Harvey Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  4 in total

1.  Ubiquinone binding site of yeast NADH dehydrogenase revealed by structures binding novel competitive- and mixed-type inhibitors.

Authors:  Tetsuo Yamashita; Daniel Ken Inaoka; Tomoo Shiba; Takumi Oohashi; So Iwata; Takao Yagi; Hiroaki Kosaka; Hideto Miyoshi; Shigeharu Harada; Kiyoshi Kita; Katsuya Hirano
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

2.  Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the Streptococcus agalactiae Respiratory Chain and Is a Potential Drug Target.

Authors:  Andrea M Lencina; Thierry Franza; Matthew J Sullivan; Glen C Ulett; Deepak S Ipe; Philippe Gaudu; Robert B Gennis; Lici A Schurig-Briccio
Journal:  mBio       Date:  2018-07-03       Impact factor: 7.867

3.  Structure of the NDH-2 - HQNO inhibited complex provides molecular insight into quinone-binding site inhibitors.

Authors:  Jessica Petri; Yosuke Shimaki; Wanting Jiao; Hannah R Bridges; Euan R Russell; Emily J Parker; David Aragão; Gregory M Cook; Yoshio Nakatani
Journal:  Biochim Biophys Acta Bioenerg       Date:  2018-04-03       Impact factor: 3.991

4.  Structure of mycobacterial CIII2CIV2 respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203).

Authors:  David J Yanofsky; Justin M Di Trani; Sylwia Król; Rana Abdelaziz; Stephanie A Bueler; Peter Imming; Peter Brzezinski; John L Rubinstein
Journal:  Elife       Date:  2021-09-30       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.